Health Dictionary Find a Doctor

Incidentaloma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]

Overview

Overview

The mainstay of treatment for adrenal incidentaloma is surgery but pre-operative medical management is needed for functional masses. Peri-operative medical management of patients with sub-clinical Cushing’s syndrome includes glucocorticoid therapy during surgery. Such patients can safely undergo surgical resection of their tumor and have their cortisol levels measured post-operatively. Preoperative medical management of patients with pheochromocytoma includes preoperative treatment to control hypertension during surgery and hypotension after it. Three medical regimens for preoperative management of pheochromocytoma: Combined alpha and beta-adrenergic blockers, calcium channel blockers, and Metyrosine. Pre-operative medical management of patients with aldosteronoma include medical therapy with mineralocorticoid receptor antagonists should be reserved for those who are unable or unwilling to undergo surgery.

Medical Therapy

Medical Therapy

The mainstay of treatment for adrenal incidentaloma is surgery but preoperative medical management is needed for functional masses.

Peri-operative medical management of patients with subclinical Cushing’s syndrome:

  • There are two approaches to deal with cases of Cushing’s syndrome:[1][2][3]
    • Patients do not require glucocorticoid therapy during surgery. Such patients can safely undergo surgical resection of their tumor and have their cortisol levels measured post-operatively.
    • This would provide an early evaluation of surgical success. Hydrocortisone may be given to the patient 30 mg in the morning and 10 mg in the afternoon until the result of the cortisol level becomes available.[4]
    • Another approach would be to cover all patients with glucocorticoids peri-operatively.[5]

Pre-operative medical management of patients with pheochromocytoma

Beta-adrenergic blocker

Pre-operative medical management of patients with primary hyperaldosteronism
Post-operative management of patients with primary hyperaldosteronism
References

References

  1. Chiodini I, Morelli V, Salcuni AS, Eller-Vainicher C, Torlontano M, Coletti F; et al. (2010). “Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism”. J Clin Endocrinol Metab. 95 (6): 2736–45. doi:10.1210/jc.2009-2387. PMID 20375210.
  2. 2.0 2.1 2.2 Nieman LK (2010). “Approach to the patient with an adrenal incidentaloma”. J Clin Endocrinol Metab. 95 (9): 4106–13. doi:10.1210/jc.2010-0457. PMC 2936073. PMID 20823463.
  3. Marko NF, Gonugunta VA, Hamrahian AH, Usmani A, Mayberg MR, Weil RJ (2009). “Use of morning serum cortisol level after transsphenoidal resection of pituitary adenoma to predict the need for long-term glucocorticoid supplementation”. J Neurosurg. 111 (3): 540–4. doi:10.3171/2008.12.JNS081265. PMID 19326985.
  4. Marko NF, Gonugunta VA, Hamrahian AH, Usmani A, Mayberg MR, Weil RJ (2009). “Use of morning serum cortisol level after transsphenoidal resection of pituitary adenoma to predict the need for long-term glucocorticoid supplementation”. J Neurosurg. 111 (3): 540–4. doi:10.3171/2008.12.JNS081265. PMID 19326985.
  5. Chiodini I, Morelli V, Salcuni AS, Eller-Vainicher C, Torlontano M, Coletti F; et al. (2010). “Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism”. J Clin Endocrinol Metab. 95 (6): 2736–45. doi:10.1210/jc.2009-2387. PMID 20375210.
  6. Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A; et al. (2016). “Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors”. Eur J Endocrinol. 175 (2): G1–G34. doi:10.1530/EJE-16-0467. PMID 27390021.
  7. Adler JT, Meyer-Rochow GY, Chen H, Benn DE, Robinson BG, Sippel RS; et al. (2008). “Pheochromocytoma: current approaches and future directions”. Oncologist. 13 (7): 779–93. doi:10.1634/theoncologist.2008-0043. PMID 18617683.
  8. Pacak K (2007). “Preoperative management of the pheochromocytoma patient”. J Clin Endocrinol Metab. 92 (11): 4069–79. doi:10.1210/jc.2007-1720. PMID 17989126.
  9. Goldstein RE, O’Neill JA, Holcomb GW, Morgan WM, Neblett WW, Oates JA; et al. (1999). “Clinical experience over 48 years with pheochromocytoma”. Ann Surg. 229 (6): 755–64, discussion 764-6. PMC 1420821. PMID 10363888.
  10. Bravo EL (2004). “Pheochromocytoma: current perspectives in the pathogenesis, diagnosis, and management”. Arq Bras Endocrinol Metabol. 48 (5): 746–50. doi:/S0004-27302004000500021 Check |doi= value (help). PMID 15761546.
  11. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H; et al. (2016). “The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline”. J Clin Endocrinol Metab. 101 (5): 1889–916. doi:10.1210/jc.2015-4061. PMID 26934393.
  12. Young WF (2007). “Primary aldosteronism: renaissance of a syndrome”. Clin Endocrinol (Oxf). 66 (5): 607–18. doi:10.1111/j.1365-2265.2007.02775.x. PMID 17492946.
  13. Mattsson C, Young WF (2006). “Primary aldosteronism: diagnostic and treatment strategies”. Nat Clin Pract Nephrol. 2 (4): 198–208, quiz, 1 p following 230. doi:10.1038/ncpneph0151. PMID 16932426.

Template:WH Template:WS

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH